Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical)

重组溶瘤单纯疱疹病毒2型 (滨会生物)

Report date: 2026/03/19 17:22:31

Base Information

Drug NameRecombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical)

Drug Alias NameoBSV2-BiTEsoHSV2-PD-L1/CD3-BsAb (Binhui Biopharmaceutical)BS-006oHSV2-BiTEsoHSV2CD3-PD-L1

ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionProgrammed death-ligand 1 blockersAnti-CD3

TargetsProgrammed death-ligand 1T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsMelanoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesWuhan Binhui Biotechnology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Binhui Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursUterine Cervical NeoplasmsMelanoma

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A